Eyenovia welcomes Dr. Julia Haller to its Board of Directors

– USA, NY –  Eyenovia, Inc. (NASDAQ: EYEN), a clinical-stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology, today announced the appointment of Dr. Julia Haller, M.D., to its Board of Directors.

“We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” said  Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. “We believe that Dr. Haller’s decades of experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader will be invaluable to the Eyenovia team as we strive to advance our late-stage ophthalmic pipeline and work towards our near-term clinical and regulatory milestones.”

“I have been familiar with Eyenovia and its MAP technology for some time now and believe the Company’s proprietary programs have the potential to become new standards of care in ophthalmic indications with significant unmet needs,” stated Dr. Haller. “I look forward to working with my fellow Eyenovia Board members and the leadership team to help create advances in the field.”

About Dr. Julia Haller

Since 2007, Dr. Haller has served as Ophthalmologist-in-Chief at Wills Eye Hospital in Philadelphia, where she holds the William Tasman, M.D. Endowed Chair. She also is a Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals.

One of the world’s most renowned retinal surgeons, Dr. Haller has published over 400 scientific articles and book chapters and innovated translational advances against blindness in many areas. Elected to the National Academy of Medicine, Dr. Haller, has been awarded the Rolex Achievement Award, the American Academy of Ophthalmology Honor Award, the AAO Senior Achievement Award, the Vitreous Society Senior Honor Award, the Crystal Apple Award of the American Society of Retina Specialists, the Kreissig Award from EURETINA, the President’s Award from Women in Ophthalmology, a Secretariat Award from the AAO, the Gertrude Pyron Award from the Retina Research Foundation/ASRS, a Lifetime Achievement Award from the AAO, the Louis Braille Award from Associated Services for the Blind, the Heed Award from the Society of Heed Fellows, the Gass Medal from the Macula Society, the Strittmatter Award from the Philadelphia Medical Society, the AAO EnergEYES Award, the WIO Suzanne Véronneau-Troutman Award, the Charles L. Schepens, MD, Award from the Retina Research Foundation/AAO and election to the Johns Hopkins Society of Scholars. She holds Chair XVI of the Academia Ophthalmologica Internationalis.

Dr. Haller serves on the board of directors of Bristol-Myers Squibb Company. She also serves as president and board member for the Women in Medicine Legacy Foundation. Dr. Haller chairs the Heed Foundation and Society of Heed Fellows, is a member of the board of directors of the College of Physicians of Philadelphia, Johns Hopkins Medical and Surgical Association, and the Philadelphia Orchestra Association, and is a member of the American Ophthalmological Society Council and the American Academy of Ophthalmology Foundation board of advisors. She is past president of the Retina Society and the American Society of Retina Specialists and was previously a member of the Board of Trustees of the Association of University Professors of Ophthalmology, as well as a founding member of Women in Retina. Her editorial board service includes RETINA, Retinal Physician, Retina Times, Ocular Surgery News, Retina Today, and Ophthalmology Times.

Dr. Haller was educated at Princeton University, where she graduated magna cum laude, and at Harvard Medical School, where she earned her M.D. She trained at the Wilmer Eye Institute at Johns Hopkins, where she served as the first female Chief Resident. She then joined the Johns Hopkins faculty, where she directed the retina fellowship program and held the Katharine Graham Chair in Ophthalmology before her current position leading Wills Eye Hospital.

About Eyenovia, Inc.

Eyenovia, Inc. is a clinical-stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology. Eyenovia is currently focused on the late-stage development of medications for presbyopia, myopia progression, and mydriasis.

For more information: https://eyenovia.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.